Alpha Tau CFO to Present at Key Biopharma Conferences in September
Event summary
- Alpha Tau CFO Raphi Levy to participate in two investor conferences in September 2026.
- Events include Citi's 2026 Biopharma Back to School Conference (Sept. 9) and H.C. Wainwright 28th Annual Global Investor Conference (Sept. 14).
- Levy will conduct 1x1 meetings and a fireside chat at the H.C. Wainwright conference.
- Alpha Tau develops Alpha DaRT, a cancer therapy using alpha-radiation for solid tumors.
The big picture
Alpha Tau's participation in high-profile biopharma conferences underscores its push to engage with investors amid growing competition in the oncology space. The company's Alpha DaRT technology, which aims to precisely target solid tumors with alpha radiation, is at a critical stage where investor confidence and regulatory progress will be key drivers of its valuation. The upcoming presentations could signal Alpha Tau's readiness to scale its commercial efforts.
What we're watching
- Investor Sentiment
- How Alpha Tau's presentations will impact investor perception of its Alpha DaRT technology.
- Commercialization Progress
- Whether Alpha Tau will provide updates on regulatory approvals or commercialization milestones.
- Competitive Positioning
- The pace at which Alpha Tau can differentiate itself in the crowded oncology therapeutics market.
Related topics